Ocular Therapeutix OCUL
NASDAQ OCUL
$6.50 -0.11 (-1.66%)
At close: Oct 23, 2026 · 4:00 PM EDT

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2016 - 2026)

Updated

Ocular Therapeutix (OCUL) recorded Gains from Sales and Divestitures of -$4.87 million in Q1 2026.

Analysis

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2016 - 2026) Analysis & Trends

On a TTM basis, Ocular Therapeutix's Gains from Sales and Divestitures came in at -$4.84 million as of Mar 31, 2026; for FY2025, it was $29,000.

  • Annual Gains from Sales and Divestitures has a four-year compound annual growth rate of 132.1% (FY2021 to FY2025).
  • Across earlier years, Gains from Sales and Divestitures came in at -$1,000 in FY2023, -$1,000 in FY2022 and $1,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Ocular Therapeutix 1.47 Bn -879.36 Mn 11.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.87 Mn
Jun 30, 2025 29,000.00
Dec 31, 2023 -2,000.00
Mar 31, 2023 1,000.00
Sep 30, 2022 1,000.00
Mar 31, 2022 -2,000.00
Dec 31, 2016 -1.27 Mn
API Access

Ocular Therapeutix Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=OCUL&period=max&api_key=YOUR_API_KEY